Nutrition and Dietetics; Endocrinology, Diabetes and Metabolism; Food Science
Abstract :
[en] ObjectivesThe effect and safety of Nasafytol®, a food supplement combining curcumin, quercetin, and Vitamin D, on hospitalized COVID-19-positive patients as support to standard of care were to be assessed.MethodsThis exploratory, open-label, randomized, controlled trial was carried out among hospitalized adults with COVID-19 infection. Participants were randomly assigned to receive Nasafytol® or Fultium® control. The improvement of the clinical condition and occurrence of (serious) adverse events were evaluated. The study was registered on <jats:ext-link>clincaltrials.gov</jats:ext-link> with the identifier NCT04844658.ResultsTwenty-five patients received Nasafytol®, and 24 received Fultium®. Demographic characteristics were well balanced between the groups. On day 14 (or at hospital leave if < 14 days), no difference was observed between groups regarding their clinical condition, fever, or the need of oxygen therapy. At day 7, however, 19 participants had been discharged from the hospital in the Nasafytol® arm compared to 10 participants in the Fultium® arm. No participants were transferred to the ICU or died in the Nasafytol® arm, vs. 4 transfers and 1 death in the Fultium® arm. The clinical condition of participants in the Nasafytol® arm had improved, as evidenced by a decrease in the COVID-19 WHO score. Interestingly, five SAEs occurred with Fultium®, while no SAE was observed with Nasafytol®.ConclusionSupplementation with Nasafytol®, in addition to standard-of-care treatment, led to a faster discharge from the hospital, improved clinical conditions of participants, and a reduced risk of serious outcomes, including transfer to the intensive care unit or death, in patients hospitalized with COVID-19.
Disciplines :
Human health sciences: Multidisciplinary, general & others
Author, co-author :
Gérain, Jean; CHIREC Hospital Group, Brussels > Department of internal Medicine
Uebelhoer, Melanie; Artialis SA
Costes, Bérénice; Artialis SA
Herman, Julie; Artialis SA
Pietri, Sandra; Artialis SA
Donneau, Anne-Françoise ; Université de Liège - ULiège > Département des sciences de la santé publique
Monseur, Justine ; Université de Liège - ULiège > Département des sciences de la santé publique > Biostatistique
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et physiopathologie - Techniques particulières de kinésithérapie ; Artialis SA
Language :
English
Title :
NASAFYTOL® supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial
Zhou F Yu T Du R Fan G Liu Y Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3, PMID: 32171076
Bayati M Noroozi R Ghanbari-Jahromi M Jalali FS. Inequality in the distribution of Covid-19 vaccine: a systematic review. IJEqH. (2022) 21. Available from::122. doi: 10.1186/s12939-022-01729-x, PMID: 36042485
WHO Solidarity Trial ConsortiumPan H Peto R Henao-Restrepo AM Preziosi MP Sathiyamoorthy V et al. Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. N Engl J Med. (2021) 384:497–511. doi: 10.1056/NEJMoa2023184, PMID: 33264556
Ader F Bouscambert-Duchamp M Hites M Peiffer-Smadja N Poissy J Belhadi D et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. (2022) 22:209–21. doi: 10.1016/S1473-3099(21)00485-0, PMID: 34534511
Beigel JH Tomashek KM Dodd LE Mehta AK Zingman BS Kalil AC et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. (2020) 383:1813–26. doi: 10.1056/NEJMoa2007764, PMID: 32445440
WHO Rapid Evidence Appraisal for COVID-19 Therapies Working GroupSterne J Murthy S Diaz JV Slutsky AS Villar J et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically ill Patients with COVID-19: a meta-analysis. JAMA. (2020) 324:1330–41. doi: 10.1001/jama.2020.17023, PMID: 32876694
RECOVERY Collaborative GroupHorby P Lim WS Emberson JR Mafham M Bell JL et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. (2021) 384:693–704. doi: 10.1056/NEJMoa2021436, PMID: 32678530
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. (2021) 397:1637–45. doi: 10.1016/S0140-6736(21)00676-0
Moscatelli F Sessa F Valenzano A Polito R Monda V Cibelli G et al. COVID-19: role of nutrition and supplementation. Nutrients. (2021) 13:976. doi: 10.3390/nu13030976
Grant WB Lahore H McDonnell SL Baggerly CA French CB Aliano JL et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. (2020) 12:988. doi: 10.3390/nu12040988, PMID: 32252338
Murai IH Fernandes AL Sales LP Pinto AJ Goessler KF Duran CSC et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. (2021) 325:1053–60. doi: 10.1001/jama.2020.26848, PMID: 33595634
Park HR Yoon H Kim MK Lee SD Chong Y. Synthesis and antiviral evaluation of 7-O-arylmethylquercetin derivatives against SARS-associated coronavirus (SCV) and hepatitis C virus (HCV). Arch Pharm Res. (2012) 35:77–85. doi: 10.1007/s12272-012-0108-9, PMID: 22297745
Qiu X Kroeker A He S Kozak R Audet J Mbikay M et al. Prophylactic efficacy of quercetin 3-β-O-d-glucoside against Ebola virus infection. Antimicrob Agents Chemother. (2016) 60:5182–8. doi: 10.1128/AAC.00307-16, PMID: 27297486
Wu W Li R Li X He J Jiang S Liu S et al. Quercetin as an antiviral agent inhibits influenza a virus (IAV) entry. Viruses. (2015) 8:6. doi: 10.3390/v8010006, PMID: 26712783
Han S Xu J Guo X Huang M. Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production. Clin Exp Pharmacol Physiol. (2018) 45:84–93. doi: 10.1111/1440-1681.12848, PMID: 28853207
Dai J Gu L Su Y Wang Q Zhao Y Chen X et al. Inhibition of curcumin on influenza a virus infection and influenza pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways. Int Immunopharmacol. (2018) 54:177–87. doi: 10.1016/j.intimp.2017.11.009, PMID: 29153953
Choi HJ Song JH Kwon DH. Quercetin 3-rhamnoside exerts antiinfluenza a virus activity in mice. Phytother Res. (2012) 26:462–4. doi: 10.1002/ptr.3529, PMID: 21728202
Babaei F Nassiri-Asl M Hosseinzadeh H. Curcumin (a constituent of turmeric): new treatment option against COVID-19. Food Sci Nutr. (2020) 8:5215–27. doi: 10.1002/fsn3.1858, PMID: 33133525
Wu S Xiao D. Effect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. (2016) 117:697–702.e1. doi: 10.1016/j.anai.2016.09.427, PMID: 27789120
Cheng AL Hsu CH Lin JK Hsu MM Ho YF She TS et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. (2001) 21:2895–900. PMID: 11712783
Andres S Pevny S Ziegenhagen R Bakhiya N Schäfer B Hirsch-Ernst KI et al. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res. (2018) 62:1700447. doi: 10.1002/mnfr.201700447, PMID: 29127724
Khan A Iqtadar S Mumtaz SU Heinrich M Pascual-Figal DA Livingstone S et al. Oral co-supplementation of curcumin, quercetin, and vitamin D3 as an adjuvant therapy for mild to moderate symptoms of COVID-19-results from a pilot open-label, randomized controlled trial. Front Pharmacol. (2022) 13:1781. doi: 10.3389/fphar.2022.898062, PMID: 35747751
WHO. WHO R&D blueprint novel coronavirus—COVID-19 THerapeutic trial synopsis. World Health Organization. (2020).
Mercola J Grant WB Wagner CL. Evidence regarding vitamin D and risk of COVID-19 and its severity. Nutrients. (2020) 12:1–24. doi: 10.3390/nu12113361
Sabico S Enani MA Sheshah E Aljohani NJ Aldisi DA Alotaibi NH et al. Effects of a 2-week 5000 IU versus 1000 IU vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate Covid-19: a randomized clinical trial. Nutrients. (2021) 13:2170. doi: 10.3390/nu13072170, PMID: 34202578
Vahedian-Azimi A Abbasifard M Rahimi-Bashar F Guest PC Majeed M Mohammadi A et al. Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: a systematic review of clinical trials. Nutrients. (2022) 14:256. doi: 10.3390/nu14020256, PMID: 35057437
Di Pierro F Derosa G Maffioli P Bertuccioli A Togni S Riva A et al. Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. Int J Gen Med. (2021) 14:2359–66. doi: 10.2147/IJGM.S318720, PMID: 34135619
Bilezikian JP Bikle D Hewison M Lazaretti-Castro M Formenti AM Gupta A et al. MECHANISMS IN ENDOCRINOLOGY: vitamin D and COVID-19. Eur J Endocrinol. (2020) 183:R133–47. doi: 10.1530/EJE-20-0665, PMID: 32755992
Sharma VK Prateeksha N Singh SP Singh BN Rao CV Barik SK. Nanocurcumin potently inhibits SARS-CoV-2 spike protein-induced cytokine storm by deactivation of MAPK/NF-κB Signaling in epithelial cells. ACS Appl Bio Mater. (2022) 5:483–91. doi: 10.1021/acsabm.1c00874, PMID: 35112841
Leyva-López N Gutierrez-Grijalva EP Ambriz-Perez DL Heredia JB. Flavonoids as cytokine modulators: a possible therapy for inflammation-related diseases. Int J Mol Sci. (2016) 17:921. doi: 10.3390/ijms17060921
Lee S Yu Y Trimpert J Benthani F Mairhofer M Richter-Pechanska P et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature. (2021) 599:283–9. doi: 10.1038/s41586-021-03995-1, PMID: 34517409
Aburto S Cisterna M Acuña J Ruíz C Viscardi S Márquez JL et al. Obesity as a risk factor for severe COVID-19 in hospitalized patients: epidemiology and potential mechanisms. Healthcare. (2022) 10:1838. doi: 10.3390/healthcare10101838
Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. eds. Ross AC Taylor CL Yaktine AL Del Valle HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (2011).